VERA - VERA

Ultime notizie per Vera Therapeutics (NASDAQ:VERA) Azioni

Vera Therapeutics

VERAMARK TECHS INC

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics Inc

VERASTEM ORD

Vera Bradley Inc

Veracyte Inc

Veradigm Inc

VERALLIA,COURBEVOIE by VERALLIA, COURBEVOIE

Verallia

Veralto Corp

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Verasity

Verastem Inc

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.64) by 32.81 percent. This is a 88.89 percent decrease over losses of $(0.45) per share from the same period last year.

Earnings

Earnings Misses

News

VERA

Vera Therapeutics Q3 EPS $(0.85) Misses $(0.64) Estimate

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and raises the price target from $72 to $75.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $75

Reported Earlier, Vera Therapeutics Prices $300M Public Offering Of 7,142,858 Class A Common Shares At $42/Share

WIIM

Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.

In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.&nbsp;

Offerings

Vera Therapeutics Plans To Commence Public Offering To Issue And Sell $300M Of Shares Of Its Class A Common Stock

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $56 to $64.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $64

On Saturday, Vera Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41562227/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of-atacicept-in-ig" rel="noreferrer noopener">of long-term follow-up</a>.
These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 and published in a&nbsp;manuscript&nbsp;in the&nbsp;Journal of the American Society of Nephrology.
Over 96 weeks, participants treated with atacicept demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and a mean annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year.
The cumulative generally favorable safety profile of atacicept remained consistent with that observed during the randomized period, with a 90% completion rate of atacicept treatment.
The company says these data support the potential for atacicept to offer long-term, comprehensive IgAN disease modification and provide further confidence in the ongoing pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN.
The company plans to initiate an ORIGIN Extend study in the fourth quarter of 2024, which will provide ORIGIN participants with extended access to atacicept before its commercial availability.
The ORIGIN 3 trial is on track to announce topline results in the second quarter of 2025, with planned FDA marketing application submission later in the year.
Earlier this year, Vera Therapeutics revealed 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).&nbsp;
Data from the OLE showed the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks&nbsp;in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36807507/whats-going-on-with-vera-therapeutics-stock-today" rel="noreferrer noopener">participants with IgAN</a>.&nbsp;
Price Action: VERA stock is up 12.2% at $46.12 at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41571498/gryphon-digital-restructures-18-million-debt-with-lender-anchorage-grants-it-board-seat" target="_blank" rel="noreferrer noopener">Gryphon Digital Restructures $18 Million Debt With Lender Anchorage, Grants It Board Seat</a></li>
</ul>

Biotech

Equities

Health Care

Movers

Trading Ideas

General

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its <a href="https://www.benzinga.com/quote/PRCT/earnings">FY24 revenue guidance</a>.
PROCEPT BioRobotics shares jumped 25% to $85.87 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares jumped 60.5% to $7.85 after the company announced a global license agreement with Novartis to advance VAV1 MGDs. The company will receive a $150 million upfront payment and is eligible for additional milestone payments.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) gained 33.6% to $12.69 after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares gained 25.5% to $5.89 after the company announced it entered into the sixth amendment to its exclusive distribution agreement with Teoxane.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 19.5% to $6.36.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 15.3% to $44.91. The stock may be moving amid possible volatility as traders evaluate his chance of winning the 2024 presidential election.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) surged 15.3% to $17.66.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 13.8% to $11.09. Ladenburg Thalmann analyst Glenn Mattson initiated coverage on Serve Robotics with a Buy rating and announced a price target of $16.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose 12.1% to $46.05 after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 10.3% to $19.21.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 10.2% to $7.03.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 9% to $18.03.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) rose 8.3% to $9.45. Canaccord Genuity analyst Brian McNamara maintained Newell Brands with a Buy and raised the price target from $12 to $13.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7% to $251.00 amid a rise in Bitcoin.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) rose 6.3% to $18.14 amid a rise in Bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Intraday Update

Markets

EYPT

GLUE

IBRX

MARA

MNSO

MSTR

PRCT

PRTA

RVNC

SERV

WULF

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Vera Therapeutics shares are trading higher after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.

<ul>
<li>Long-term improvements observed in the quartet of findings defining disease modification supports atacicept&#39;s potential to prevent kidney failure in patients with IgAN;</li>
<li>Long-term results from the ORIGIN Phase 2b study were simultaneously published in the&nbsp;Journal of the American Society of Nephrology;</li>
<li>Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET</li>
</ul>

Reported Saturday, Vera Therapeutics Reveals 96-Week eGFR Stabilization In IgAN Patients with Atacicept: ORIGIN Phase 2b Study Findings Presented At ASN Kidney Week

Scotiabank analyst Greg Harrison initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Sector Outperform rating and announces Price Target of $60.

Initiation

Scotiabank Initiates Coverage On Vera Therapeutics with Sector Outperform Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and maintains $107 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target

Vera Therapeutics To Present Long-term Results From Origin Phase 2B Clinical Trial Of Atacicept For Treatment Of IgAN

This program is expected to build on the positive data reported to date from the ongoing ORIGIN Phase 2b and 3 clinical program developing atacicept to treat patients with IgAN, by extending into a broader population of IgAN and other autoimmune kidney indications.

Vera Therapeutics Reports Expansion Of Its Development Pipeline For Its Lead Asset, Atacicept

Vera Therapeutics shares are trading higher after the company announced it will host an in-person R&D day to discuss the potential expansion for Atacicept.

Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an in-person and virtual R&amp;D Day in New York, NY at 8:00 AM ET on Wednesday, October 2, 2024. To register, <a href="https://www.globenewswire.com/Tracker?data=EhLleWVDZ6cQRp-3ShbGRdxhXtQmSDMbbGKb5ona2p3lCdKyDeXpaEb0uCMas_9HkTg-iLCPEkI2S5qpe0x6nJm9mkYcOidYXIy_70SjwMzJO6WpZy1-K_f34bF1SVhV">click here</a>. &nbsp;
The event will feature Jonathan Barratt, MD, PhD, FRCP (University of Leicester), Richard Lafayette, MD, FACP (Stanford University Medical Center), and Brad Rovin, MD (Ohio State University Wexner Medical Center), who will join the company's management team to discuss Vera's expanded atacicept R&amp;D activities outside of the ORIGIN Phase 2b and Phase 3 clinical program.

Events

Vera Therapeutics To Host In-Person R&D Day To Discuss Potential Indication Expansion For Atacicept On October 2, 2024

<ul>
<li>On track to announce topline results from ORIGIN 3 trial in Q2 2025 &nbsp;</li>
<li>Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024</li>
</ul>
BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.

Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN

Vera Therapeutics (VERA) announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300M of shar...

Vera Therapeutics announces $300M offering of Class A common stock

17:32 EDT Vera Therapeutics (VERA) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...

Vera Therapeutics files automatic mixed securities shelf

Vera Therapeutics announces proposed public offering of class A common stock

Vera Therapeutics ( ($VERA) ) has provided an announcement. Vera Therapeutics announced promising long-term results from their Phase 2b ORIGIN tria...

Vera Therapeutics Advances Atacicept with Promising Trial Results

The deal priced below last closing price of $42.97. JPMorgan, Goldman Sachs and Evercore ISI are acting as joint book running managers for the offe...

Vera Therapeutics 7.14M share Secondary priced at $42.00

Vera Therapeutics prices $300M offering at $42 per share

Vera Therapeutics reports Q3 results

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VERA stock, giving a Buy rating on November 4. Rami Katkhuda has given...

Vera Therapeutics: Strong Buy Rating Backed by Financial Stability and Promising Atacicept Data

Vera Therapeutics (VERA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ritu Baral fro...

Vera Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating

Vera Therapeutics, Inc. ( ($VERA) ) has released its Q3 earnings. Here is a breakdown of the information Vera Therapeutics, Inc. presented to its i...

Vera Therapeutics Advances in Autoimmune Treatment

Press Releases

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Comments

Vera Therapeutics

Notizie

Ultime notizie per Vera Therapeutics (NASDAQ:VERA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO